Over 1000 Orphan Drugs in Clinical Trials in the US - Eylea, Actimmune, Ravicti Among Key Approved Therapies
07 août 2023 06h43 HE
|
Research and Markets
Dublin, Aug. 07, 2023 (GLOBE NEWSWIRE) -- The "US Orphan Drugs Market, Drugs Sales, Price, Dosage & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering. ...
Avexitide: A 31-amino Acid Peptide that Selectively Targets and Blocks GLP-1 Receptors - Emerging Drug Insights and Market Forecasts, 2019-2022 & 2023-2032
01 août 2023 06h28 HE
|
Research and Markets
Dublin, Aug. 01, 2023 (GLOBE NEWSWIRE) -- The "Avexitide Emerging Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering. "Avexitide Emerging...
Nytt antal aktier och röster i IBT
31 juil. 2023 04h00 HE
|
Infant Bacterial Therapeutics AB
Antalet aktier och röster i Infant Bacterial Therapeutics AB (publ) har förändrats med anledning av den nyligen genomförda företrädesemissionen (för mer information, se bolagets pressmeddelande den 4...
New number of shares and votes in IBT
31 juil. 2023 04h00 HE
|
Infant Bacterial Therapeutics AB
The number of shares and votes in Infant Bacterial Therapeutics AB (publ) has changed due to the recently completed rights issue (for further information, see the company’s press release on 4 July...
Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites
28 juil. 2023 08h00 HE
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company...
Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement
24 juil. 2023 07h30 HE
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage...
Completion of Enrolment and Treatment in the Phase 1 Study of MTX110 in the Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas (DMGs)
10 juil. 2023 08h00 HE
|
Biodexa Pharmaceuticals PLC
10 July 2023 Biodexa Ltd(“Biodexa” or the “Company”) Completion of Enrolment and Treatment in the Phase 1 Study of MTX110 in theTreatment of Children with Newly Diagnosed Diffuse Midline Gliomas...
Results of Appeal of Delisting Determination
06 juil. 2023 16h30 HE
|
Biodexa Pharmaceuticals PLC
6 July 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Results of Appeal of Delisting Determination Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical...
Publication of Manuscript from the PNOC015 (a.k.a. MTD-201) Study in Patients with Diffuse Midline Glioma (DMG)
06 juil. 2023 08h15 HE
|
Biodexa Pharmaceuticals PLC
6 July 2023 Biodexa Ltd(“Biodexa” or the “Company”) Publication of Manuscript from the PNOC015 (a.k.a. MTD-201) Study in Patients with Diffuse Midline Glioma (DMG) Biodexa Pharmaceuticals PLC...
IBT announces outcome of its rights issue
04 juil. 2023 02h30 HE
|
Infant Bacterial Therapeutics AB
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND,...